Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

532
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
532
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

773
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
773
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.6K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

650
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
650
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

792
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
792

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes.

American journal of preventive cardiology·2026
Same author

AI-quantified Myosteatosis at CAC CT for Prediction of Atrial Fibrillation and Heart Failure: The Multi-Ethnic Study of Atherosclerosis.

Radiology. Cardiothoracic imaging·2026
Same author

LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.

Physiological reports·2026
Same author

Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes.

Clinical & translational immunology·2026
Same author

AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke.

Stroke·2026
Same author

Modulating adaptive immunity by targeting plaque macrophages to reduce atherosclerosis progression.

European heart journal·2026

Related Experiment Video

Updated: Mar 2, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.7K

Vaccine against arteriosclerosis: an update.

Kuang-Yuh Chyu1, Paul C Dimayuga1, Prediman K Shah2

  • 1Oppenheimer Atherosclerosis Research Center, Division of Cardiology, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Therapeutic Advances in Vaccines
|May 19, 2017
PubMed
Summary
This summary is machine-generated.

Active immunization targeting antigens involved in atherosclerosis shows promise for altering disease progression. This review explores preclinical vaccine strategies and their potential for clinical use in managing atherosclerosis.

Keywords:
apolipoprotein B-100atherosclerosisimmunizationlow-density lipoprotein

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.7K
Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice
07:51

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice

Published on: January 13, 2012

21.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.7K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.7K
Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice
07:51

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice

Published on: January 13, 2012

21.1K

Area of Science:

  • Cardiovascular immunology
  • Atherosclerosis research
  • Vaccine development

Background:

  • Immune responses to endogenous and exogenous antigens play key roles in the development of atherosclerosis.
  • Both proatherogenic and atheroprotective immune mechanisms are involved in the disease process.

Purpose of the Study:

  • To review studies investigating antigens for vaccine formulations aimed at reducing atherosclerosis in preclinical models.
  • To discuss the potential clinical applications, opportunities, and challenges of active immunization strategies for atherosclerosis.

Main Methods:

  • Review of experimental and clinical investigations on immune-mediated mechanisms in atherogenesis.
  • Analysis of preclinical studies testing vaccine formulations targeting specific antigens.
  • Examination of the translational potential for clinical application.

Main Results:

  • Preclinical studies demonstrate that active immunization against certain antigens can modulate atherosclerosis.
  • Identification of key antigens with potential therapeutic value in vaccine strategies.

Conclusions:

  • Active immunization represents a novel therapeutic paradigm for atherosclerosis.
  • Further research is needed to overcome challenges and translate preclinical findings into effective clinical treatments for atherosclerosis.